Collegium Pharmaceutical (Collegium Pharmaceutical) Total Liabilities : $892.1 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Collegium Pharmaceutical Total Liabilities?

Collegium Pharmaceutical's Total Liabilities for the quarter that ended in Mar. 2024 was $892.1 Mil.

Collegium Pharmaceutical's quarterly Total Liabilities declined from Sep. 2023 ($998.71 Mil) to Dec. 2023 ($947.88 Mil) and declined from Dec. 2023 ($947.88 Mil) to Mar. 2024 ($892.08 Mil).

Collegium Pharmaceutical's annual Total Liabilities increased from Dec. 2021 ($489.15 Mil) to Dec. 2022 ($979.29 Mil) but then declined from Dec. 2022 ($979.29 Mil) to Dec. 2023 ($947.88 Mil).

Collegium Pharmaceutical Total Liabilities Historical Data

The historical data trend for Collegium Pharmaceutical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical Total Liabilities Chart

Collegium Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

218.87

457.81

489.15

979.29

947.88

Collegium Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,034.57	1,013.11	998.71	947.88	892.08

Collegium Pharmaceutical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Collegium Pharmaceutical's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	457.915	+	(489.962	+	-5.6843418860808E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	947.9

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1143.308	-	195.431
	=	947.9

Collegium Pharmaceutical's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	446.436	+	(445.645	+	5.6843418860808E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	892.1

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1114.25	-	222.169
	=	892.1

Collegium Pharmaceutical Total Liabilities Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Collegium Pharmaceutical (Collegium Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (NAS:COLL) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

354:Germany

Address

100 Technology Center Drive, Stoughton, MA, USA, 02072

Website

https://www.collegiumpharma.com

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.

Executives

Scott Dreyer	officer: EVP & Chief Commercial Officer	780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Joseph Ciaffoni	director, officer: President and CEO	100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Shirley R. Kuhlmann	officer: EVP and General Counsel	780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Tupper Colleen	officer: EVP & Chief Financial Officer	C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Garen G Bohlin	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Rita J. Balice-gordon	director	C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
John A. Fallon	director	C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
John Gordon Freund	director	125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Gwen A Melincoff	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Neil F. Mcfarlane	director	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Thomas B Smith	officer: EVP and Chief Medical Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612
Richard Malamut	officer: EVP and Chief Medical Officer	100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Alison B Fleming	officer: Vice President, Product Devlp	780 DEDHAM STREET, SUITE 800, CANTON MA 02021